1. Data & Insights

New Drug Launches in a Self-Pay World: Why Access Strategy Matters as Much as Innovation

Written by Posted on Less than 0 min read

Today’s guest post comes from Laura Jensen, Chief Commercial Officer and President, Pharma Solutions at GoodRx.

Laura argues that patient self-pay has evolved from a temporary bridge to a core access strategy for new drug launches. She examines how manufacturer-funded self-pay offers can be operational from day one.

Click here to learn more about GoodRx’s access and affordability solutions.

Read on for Laura’s insights.

Read more »

© 2006-2026 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

       
View Original Article
Post Views: 33
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Trends & External Forces

The FTC Blows Up Express Scripts’ PBM Model—and Launches the Net Pricing Drug Channel

Earlier today, the Federal Trade Commission (FTC) announced an extraordinary settlement with Express Scripts that fundamentally reshapes its pharmacy benefit management (PBM) business—and by extension, the entire drug channel. The settlement addresses virtually every warped incentive that we have been covering on Drug Channels for the past 20 years. I summarize them below, but it’s […]
2 min read
0
  1. Data & Insights

Informa Connect’s PBM Contracting Summit

Informa Connect’s PBM Contracting Summit December 9-10, 2025 | Chicago, IL (Pre-Summit Workshop on December 8th) Drug Channels readers save 10% with code 25DRCH10* Informa Connect’s PBM Contracting Summit returns to Chicago this December! Join the industry as expert speakers navigate the complex PBM landscape, gaining unparalleled strategies to enhance patient care and effectively manage […]
3 min read
0
  1. Data & Insights

Preorder Now: DCI’s 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

On October 14, 2025, Drug Channels Institute will release our 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This report—our sixteenth edition—is the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry. With 9 chapters, 400+ pages, 187 exhibits, and 850+ endnotes, this report is unmatched in […]
3 min read
0
  1. Data & Insights

Vanishing Act: Why Small Pharmacies Exited Medicare Part D Networks for 2025

Abracadabra! Small pharmacies have ghosted Medicare Part D’s preferred networks—no farewell party, no breakup text, just a quiet exit. A few months ago , DCI highlighted how the largest pharmacy chains are participating as preferred cost sharing pharmacies in the 2025 stand-alone prescription drug plan (PDP) networks. Today, we update our exclusive analysis of how […]
2 min read
0
  1. Data & Insights

2024 Gross-to-Net Realities at 9 Top Drugmakers: A New Era of Market Access

It’s time for Drug Channels’ annual update on drug pricing trends at the largest pharmaceutical manufacturers. This year’s review includes the following nine companies: Bristol Myers Squibb, Eli Lilly and Company, Genentech, GlaxoSmithKline, Johnson & Johnson, Sanofi, Takeda, Teva, and UCB. You can find links to each company’s data below. These data highlight divergent trends […]
3 min read
0
  1. Trends & External Forces

Pharma’s Direct-to-Consumer Future Runs Through GoodRx

Today’s guest post is from Laura Jensen, Chief Commercial Officer and President of Pharma Solutions at GoodRx. Laura shares her perspective on how direct-to-consumer (DTC) strategies are evolving and the role that platforms like GoodRx can play in improving access. Click here to learn more about GoodRx’s DTC solution for pharmaceutical manufacturers.  Read on for […]
2 min read
0
  1. Trends & External Forces

Informa Connect’s Patient Assistance & Access Programs (PAP)

Informa Connect’s Patient Assistance & Access Programs (PAP) March 18-20, 2025 | Sheraton Philadelphia Downtown PA Pre-Conference Workshops on March 17, 2025 Drug Channels readers save 10% on their registration with code 25DC10 When it comes to patient affordability, it’s difficult to imagine a more complex time for our industry. Navigating policy updates, disarming AFPs, […]
3 min read
0
  1. Trends & External Forces

Large Chains’ Position in 2025’s Part D Pharmacy Networks: Supermarkets Take the Lead in a Shrinking PDP Market

In Medicare Part D in 2025: Preferred Pharmacy Networks Fade in a Collapsing PDP Market, I documented the Inflation Reduction Act’s (IRA) disruption to Medicare Part D prescription drug plans (PDPs). Today, we examine the seven largest retail chains’ participation in the 12 major 2025 Part D networks that the five largest plan sponsors will […]
3 min read
0
  1. Trends & External Forces

How the Perfect Storm Will Impact Patient Support Programming in 2025 and Beyond

Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx. Chris examines three key trends that will affect patient support programs: the Inflation Reduction Act (IRA), legal/regulatory battles over copay adjustment programs, and uncertainties following a national election. He then outlines three actions that should guide manufacturers’ preparation. To learn more, register […]
2 min read
0
  1. Media & Marketing

Follow the 340B Prescription Dollar: How PBMs Profit from 340B Contract Pharmacies (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s Drug Channels Outlook 2025 live video webinar. During the webinar, I’ll provide an update the 340B program, which continues to defy gravity. Click here to see the original post. In my recent The 340B Drug Pricing Program: Trends, Controversies, and Outlook video webinar, I […]
2 min read
0
  1. Corporate Strategy

Inside the 2025 PSAO Market: How Wholesalers Shape Pharmacy–PBM Relationships

Pharmacy services administrative organizations (PSAOs), which operate between pharmacy benefit managers (PBMs) and smaller pharmacies, are among the most mysterious—and misunderstood—intermediaries in our complex U.S. drug channel. Adding to the mystery: the largest PSAOs are owned by the three multi-billion dollar, public companies that also dominate pharmaceutical distribution—Cencora, Cardinal Health, and McKesson. These companies sit […]
2 min read
0
  1. Shopper & Customer

From Cost Center to Insights Center: How Patient Support Will Go Beyond the Call in 2026

Today’s guest post comes from Brok Vandersteen, Vice President of Business Development at AssistRx. Brok argues that in 2026, traditional patient support program (PSP) models must evolve beyond task execution to deliver actionable insights, adaptive access strategies, and measurable ROI. He outlines four key considerations for transforming PSPs from cost centers into insight-driven engines of […]
2 min read
0
  1. Media & Marketing

340B Hit $81 Billion in 2024: Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth (VIDEO)

Yesterday, I published 340B Hit $81 Billion in 2024 (+23%): Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth. For those who prefer watching to reading, I asked AI to turn our latest 340B analysis into a tidy little video. Let me know what you think of this format and whether […]
2 min read
0
  1. Department: HBC

The 340B Contract Pharmacy Market in 2025: Big Chains and PBMs Tighten Their Grip (rerun)

This week, I’m rerunning some popular posts while I put the finishing touches on DCI’s 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post from June 2025. The 340B Drug Pricing Program has emerged as a growing source of profits for pharmacies and pharmacy benefit managers (PBMs). Drug […]
2 min read
0
  1. Shopper & Customer

Best Practices for Successfully Transitioning a Patient Services Hub

Today’s guest post comes from Josh Marsh, Vice President and General Manager, Sonexus™ Access and Patient Support at Cardinal Health Josh discusses challenges manufacturers may face when outsourcing patient support programs. He outlines a process that smoothly transitions hubs and minimizes disruptions for patients and healthcare providers. To learn more, download the 3-step guide to […]
2 min read
0
  1. Data & Insights

White Bagging Update 2024: Providers’ Pushback Preserves Buy-and-Bill

Time for DCI’s annual update on the channels for provider-administered drugs. Below, I review the latest data on 2024 trends and compare them to the pre-pandemic figures. For 2024, payers report that specialty pharmacies—via white and clear bagging—have displaced buy-and-bill for a meaningful share of commercial covered lives utilizing provider-administered oncology drugs. However, provider pushback […]
2 min read
0
  1. Data & Insights

From Barriers to Bridges: Rethinking Medication Access for 2025

Today’s guest post comes from Mike Cohn, Vice President, Network Operations at CoverMyMeds. Mike shares key takeaways on patient access and affordability from CoverMyMeds’ 2025 Medication Access Report. He focuses on the systemic fragmentation that exists across payers, providers, and pharmacies. Mike explains how these silos delay treatment and lead to increased out-of-pocket costs. To […]
2 min read
0
  1. Media & Marketing

The Top 15 Specialty Pharmacies of 2024: How PBMs, Health Systems, and Independents Are Shaping the Market

Drug Channels Institute’s (DCI’s) latest analysis reveals that PBM-affiliated specialty pharmacies continue to dominate the dispensing of specialty drugs. DCI has identified nearly 1,900 dispensing locations with specialty pharmacy accreditation. Below, we share DCI’s latest analysis of the top 15 specialty pharmacies, including updated market shares and revenue estimates. As in prior years, pharmacies linked […]
2 min read
0
  1. Data & Insights

No More Delays: Accelerating Therapy Starts by Embedding Hub Services in Provider Workflows

Today’s guest post comes from Shabbir Ahmed, Chief Commercial Officer at CareMetx. Shabbir explains the barriers that providers face when dealing with branded portals for multiple products. He then maintains that patients can access new therapies more quickly when the manufacturer relies on a brand-agnostic hub connected to a large network of providers and integrated […]
2 min read
0
  1. Trends & External Forces

2024 Gross-to-Net Realities at 9 Top Drugmakers: A New Era of Market Access (rerun)

This week, I’m rerunning some popular posts while I put the finishing touches on DCI’s 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post from July 2025. It’s time for Drug Channels’ annual update on drug pricing trends at the largest pharmaceutical manufacturers. This year’s review includes the […]
3 min read
0
Next